Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — World AMR Congress 2023
25 slides from Recce Pharmaceuticals's conference presentation, September 2023
Slide 1: Breaking the Paradigm For New Anti-Infectives
Breaking the Paradigm For New Anti-Infectives Alan W Dunton, MD Non-Executive Director and Chief Medical Advisor September 2023
Slide 2: Disclaimer
Disclaimer DISCLAIMER This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this pre
Slide 3: Lack of Novel/Effective Antibiotics in Development
Lack of Novel/Effective Antibiotics in Development Why can’t we have an antibiotic which doesn’t create resistance? ~27 antibiotics under development in clinical trials against pathogens considered critical by World Health Organisation such as Acinetobacter baumannii and Pseudomonas aeruginosa. 6 ou
Slide 4: About Recce Pharmaceuticals Ltd
About Recce Pharmaceuticals Ltd “To address the global health threat of antimicrobial resistance with a revolutionary portfolio of synthetic anti-infectives” • Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a new class of Synthetic Anti-Infectives, protected by Composition of Matter Pa
Slide 5: What is the RECCE platform technology?
What is the RECCE® platform technology? • Synthetic antibiotics, not derived from nature - limited risk of resistance. Basic structure • Derived from polymer chemistry expertise and vision of the founder, Graham Melrose, PhD. • Former Executive Director and Head of Research at Johnson & Johnson Aust
Slide 6: RECCE 327 Faster Acting than Existing Antibiotics
RECCE® 327 Faster Acting than Existing Antibiotics No prolonged exposure needed, minimizing possibility of toxicity. Activity seen in just 10 minutes *Xen14 (a reduction in luminescence correlates with decrease in cell viability) 5 *All compounds used at 2X Minimum Inhibitory Concentration (MIC)
Slide 7: RECCE Rapidly Kills Non-growing E. coli ATCC 25922
RECCE® 327 Rapidly Kills Non-growing E. coli ATCC 25922 Viable Bacteria (CFU/ml) Exposure Time (Minutes) “Many antibiotics will not kill non-growing cells… R327 kills non-growing cells and kills them very rapidly and irreversibly” Marc Sharp, PhD, Chief Scientific Officer, Linnaeus Bioscience 6
Slide 8: S. aureus XEN36 treated with RECCE
S. aureus XEN36* treated with RECCE® 327 “Very rapid decrease in ATP levels, correlated with a very rapid decrease in viable bacterial counts” Marc Sharp, PhD, Chief Scientific Officer, Linnaeus Bioscience *Staphylococcus aureus Xen36 was derived from the parental strain Staphylococcus aureus ATCC 4
Slide 9: Bactericidal Effect of RECCE on ESKAPE Pathogens
Bactericidal Effect of RECCE® 327 on ESKAPE Pathogens Enterococcus faecium Staphylococcus aureus Klebsiella pneumoniae Control Control Control 4000 ug/ml 2000 ug/ml 8000 ug/ml 2000 ug/ml 1000 ug/ml 4000 ug/ml 1000 ug/ml 500 ug/ml 2000 ug/ml 500 ug/ml 250 ug/ml 1000 ug/ml 250 ug/ml 125 ug/ml 500 ug/m
Slide 10: RECCE Activity Against Escherichia coli
RECCE® 327 Activity Against Escherichia coli • E. coli grows fast. Eukaryotic cells healthy Without R327 R327 (3,000 ppm) and not affected. • R327 at 3,000 ppm shown to be highly effective against E. coli without affecting growing, healthy eukaryotic cells. • R327 rapidly and irreversibly shuts down
Slide 11: How does the RECCE technology work?
How does the RECCE® technology work? Stage 1 Stage 2 R327 arrests cell growth and R327 disrupts bacterial cellular • Novel mechanism which targets rapid access to and permeabilizes cell membranes energetics, depleting ATP shut down of bacterial energy production (ATP) which results in bacterial deat
Slide 12: RECCE Concentrates Safely in the Urine
RECCE® 327 Concentrates Safely in the Urine Intravenous Formulation – Phase I Results show R327 Ideal for UTI /Urosepsis • No serious adverse events noted in single-dose Ph I clinical trial – 80 healthy male subjects • Safe up to and including 6,000mg using a 1-hour infusion • High concentrations of
Slide 13: RECCE Kills E. coli within Minutes in Human Urine
RECCE® 327 Kills E. coli within Minutes in Human Urine Efficacy in Humans with UTI can be predicted E. coli Clinical Isolate Treated with RECCE® 327 in Urine 10.00 9.00 8.00 Viable Bacteria (Log CFU/ml) 7.00 6.00 5.00 4.00 3.00 2.00 0 5 10 15 20 25 30 35 40 45 50 55 60 Exposure Time (minutes) Untrea
Slide 14: Independent Study Undertaken on R327 sub-MIC
Independent Study Undertaken on R327 sub-MIC Conducted by Leading Experts in Bacterial MoA Analysis • Recce Pharmaceuticals and Linnaeus Bioscience Inc. performed a daily sub-MIC serial passaging experiment for 30 days using R327 • No lasting change in the MIC to R327 was found • Repeat/new experime
Slide 15: RECCE Anti-Infectives Have a Range of Formulations
RECCE® Anti-Infectives Have a Range of Formulations Suitable for Various Indications Intravenous Topical Gel Topical Liquid Aerosol for inhalation Aerosol and liquid for intranasal administration 14
Slide 16: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 0 Day 0 After 24 hours After 30 days Pre-treatment First Recce Gel Application Post Treatment Post Treatment infection Gel Applied Complete • Patient Y unresponsive to 4 x daily Cephalexin for 10 days – Infection spreading and hospi
Slide 17: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 7 Day 10 Day 14 Day 0 – Recce treatment Day 7 – Recce treatment Day 10 – Recce treatment Day 14 – Recce treatment Significant bacterial infection Initial redness and swelling No signs of infection, no signs of pus Wound impr
Slide 18: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 7 Day 14 Day 21 Day 0 – Pre-treatment wound swab Day 7 – Recce treatment Day 14 – Recce treatment Day 21 – Recce treatment Growing culture of Gram-positive and Initial redness and swelling of the No signs of bacterial growth
Slide 19: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 3 Day 7 Significant bacterial infection Redness and swelling Left femoral Day 0 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment Significant bacterial infection, redness and swelling Initial redness and swelli
Slide 20: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Pre-Treatment Day 3 Day 7 Day 1 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment Osteomyelitis (serious infection of the bone), signs of Wound drying up with infection clearing, toe Wound completely dried up, no signs of biofil
Slide 21: Fast-acting, Broad-Spectrum Platform Addresses Serious Bacterial Infections
Fast-acting, Broad-Spectrum Platform Enables Recce to address Serious, Life Threatening, and/or Resistant Bacterial Infections Intravenous Products – Potential Indications Topical Products – Potential Indications • Urinary Tract Infections: complicated, • Infected burn wounds recurrent • Complicated
Slide 22: Robust Worldwide Intellectual Property Portfolio
Robust Worldwide Intellectual Property Portfolio Recce’s patent portfolio contains over 40 patents and patent applications in the world’s major markets. Patent Patent Patent Expiry Expiry Expiry Filed Family 1 Family 2 Family 3 Family 1 group relates to the Company’s Unique and Highly Australia ✓ 20
Slide 23: Board Structure
Board Structure Michele Dilizia – Executive Director & Chief Scientific Officer Dr John Prendergast – Executive Chairman BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) Dr Justin Ward – Executive Director & Head of QA/QC James Graham – Chief
Slide 24: Conclusions
Conclusions Recce’s Portfolio of Anti-Infectives • Rapid onset of effect and a broad spectrum of activity (including against ESKAPE pathogens) • Potentially effective as a single-dose • Straightforward, inexpensive manufacturability, starting product from USA • Technology of Synthetic Anti-Infective
Slide 25: Thank you
Thank you @0@ recce.com.au